To compare the effects of continuing versus discontinuing sitagliptin when initiating and intensively titrating insulin glargine.
| INTRODUCTION
Type 2 diabetes is a progressive disease and, over time, most patients will require intensification of therapy to maintain glycaemic control.
While clinical practice guidelines provide comprehensive recommendations for the intensification of pharmacological treatment which take into consideration drug-specific and patient factors, they provide limited guidance regarding the continuation or discontinuation of antihyperglycaemic agents (AHAs) that are part of a patient's existing regimen at the time of initiating insulin therapy. 1, 2 Nonetheless, continuation of oral agents is consistent with practice guidelines, and when insulin therapy is initiated, basal insulin is often prescribed for use in combination with metformin and sometimes additional AHAs.
Prior to the initiation of insulin, dipeptidyl peptidase-4 (DPP- 4) inhibitors are commonly used as part of dual or triple combination therapy with metformin to achieve glycaemic control; therefore, when combination oral therapy becomes inadequate for maintaining glycaemic control and insulin therapy is initiated, a commonly encountered decision is that of whether to continue a DPP-4 inhibitor. There are limited data available that provide an evidence base with regard to this clinical issue.
The continued use of DPP-4 inhibitors when initiating insulin therapy has theoretical advantages. While the use of basal insulin targets the reduction of fasting and pre-meal blood glucose (BG) levels, the progressive diminution in insulin secretory capacity in patients with type 2 diabetes can lead to poor postprandial and, as a consequence, overall glycaemic control. DPP-4 inhibitors, which improve postprandial glycaemic control by stabilizing the endogenous incretin peptides glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), directly address this pathophysiology. In addition, it has been shown that event rates of hypoglycaemia increase as basal insulin is progressively titrated to achieve glycated haemoglobin (HbA1c) targets consistent with scientific society guidance, [3] [4] [5] [6] which probably plays a role in the inability to achieve glycaemic goals in many patients. Continuation of DPP-4 inhibitors might result in reduced rates of hypoglycaemia at lower HbA1c targets because of a reduced requirement for insulin and/or because of the glucagonotropic effects of GIP during hypoglycaemia. [7] [8] [9] [10] While there may be advantages to continuing DPP-4 inhibitors when initiating basal insulin, DPP-4 inhibitors are often discontinued under these circumstances. 11 The impact of discontinuing DPP-4
inhibitors when initiating basal insulin on glycaemic control and hypoglycaemia has not been studied. The CompoSIT-I (Comparison of Sitagliptin vs. placebo during Initiation of Insulin) trial was designed to evaluate the impact of continuation versus discontinuation of sitagliptin when initiating and intensively titrating insulin glargine therapy.
2 | METHODS
| Study population
At screening, eligible patients were men and female, aged ≥18 years, 
| Study design
The study was a multinational, double-blind, randomized, placebocontrolled trial conducted at 149 sites in 22 countries (Supporting Information Table S1 ). The study included a 1-week screening period, a 4-to 8-week run-in period (for participants taking metformin + a DPP-4 inhibitor other than sitagliptin, AE a sulphonylurea at screening, a 4-week period for sitagliptin initiation and dose stabilization and sulphonylurea washout if required; for participants taking metformin + sulphonylureas at screening, an 8-week period for sitagliptin initiation and dose stabilization and sulphonylurea washout was included;
for participants taking metformin + sitagliptin at screening, no run-in period was required), a 30-week double-blind treatment period and 2-week follow-up were included (Supporting Information Figure S1 ).
Participants on a fixed-dose combination of a DPP-4 inhibitor and metformin (immediate-release or extended-release) were switched to co-administration of sitagliptin and metformin immediate-release or extended-release as appropriate. Participants were trained to perform self-monitoring of BG using a BG meter and to self-administer insulin subcutaneously. After the run-in period, participants were randomized centrally, using an interactive voice response system, in a 1:1 ratio, to either continue sitagliptin or switch to a placebo matching sitagliptin.
All participants initiated insulin glargine (LANTUS, U-100, Sanofi, Bridgewater, NJ, USA) on the evening of the day of randomization with a starting dose of 10 units. Participants were instructed to administer their insulin in the evening at the same time every day.
Participants were instructed to titrate insulin throughout the entire study period, based on their pre-breakfast fasting BG level using an algorithm that targeted a fasting value of 4.0 to 5.6 mmol/L. 
| Efficacy objectives
All objectives of this study were to assess the effects of continuing sitagliptin relative to discontinuing sitagliptin after 30 weeks. The primary objectives were to assess the change from baseline in HbA1c and the event rate of documented symptomatic hypoglycaemia with BG ≤3.9 mmol/L. "Event rate" was defined as the total number of events (including multiple events in the same participant) divided by the total follow-up time.
Secondary objectives were to assess the incidence of documented hypoglycaemia (with symptoms and regardless of symptoms) with a BG ≤3.9 mmol/L, the event rate and incidence of documented hypoglycaemia (with symptoms and regardless of symptoms) with BG 
| Safety evaluations
Safety assessment included adverse events, changes from baseline in standard laboratory blood chemistry (eg, electrolytes, liver and renal safety tests), lipid panel and vital signs (including systolic and diastolic blood pressure and heart rate) and body weight.
| Statistical analyses
The population for all efficacy endpoints included all randomized participants who received at least one dose of study treatment and, with the exception of the endpoint of hypoglycaemia, who had at least one measurement of the respective endpoint. Type 1 error was controlled at 0.05 using the method described by Maurer and Bretz
12
(Supporting Information Figure S2 ). Safety analyses included all randomized and treated participants.
For the analyses of change from baseline in HbA1c, a longitudinal data analysis model 13 was used to evaluate the non-inferiority For event rate analyses related to hypoglycaemia, a negative binomial regression model with a log-link function was used, with the number of events for each participant being the response variable.
The model included terms for treatment, race, region, AHA treatment at screening, baseline HbA1c value, baseline body weight, and an offset for follow-up time (on the natural log scale).
For incidence analyses related to HbA1c goals and hypoglycaemia, the Miettinen and Nurminen method 14 was used. For endpoints related to HbA1c goals, missing values at week 30 were imputed as "not at goal". For endpoints related to hypoglycaemia, a missing data imputation method was used as described in the Supporting Information.
A sample size of~350 participants per treatment group was estimated to provide >99% power to establish that continuing sitagliptin was non-inferior to withdrawing sitagliptin and 93% power for HbA1c superiority, assuming an underlying treatment difference of 0% and −0.3%, respectively. The study had 93% power to detect a rate ratio of 0.6 for documented symptomatic hypoglycaemia events with BG ≤3.9 mmol/L. Baseline demographics and efficacy variables were balanced between treatment groups ( Table 1 ). The participants' mean AE SD age was 58.3 AE 9.6 years,~50% were female, the mean AE SD baseline
HbA1c was 72.6 AE 10.2 mmol/mol (8.8 AE 0.9%), body mass index was 31.1 AE 5.8 kg/m 2 , and duration of diabetes was 10.8 AE 6.8 years. Between-group differences in HbA1c were observed by week 6, the first post-randomization measurement ( Figure 2A ).
| Efficacy
The event rate of documented symptomatic hypoglycaemia with BG ≤3.9 mmol/L over 30 weeks was significantly lower in the sitagliptin group compared with the placebo group (event rate ratio = 0.73; P = 0.039 [ Table 2 ]). Two participants (both in the sitagliptin group)
were excluded from the primary analysis of this endpoint because of missing values for a model covariate (race); in a post hoc analysis of a model in which race was excluded, thereby including the two participants noted above, the event rate ratio was 0.76 (P = 0.073). In a post hoc analysis of the time course of hypoglycaemia events by 6-week intervals, which corresponded to scheduled clinic visits (Supporting Information Figure S3 ), during the initial 6 weeks of insulin titration, when insulin doses were lowest, the event rates were also lowest in both groups. With further insulin titration, the event rates increased in both treatment groups, but were notably lower in the sitagliptin group compared with the placebo group in all but one of the periods (weeks [18] [19] [20] [21] [22] [23] [24] . Tables S2 and S3 ).
The first key secondary objective was the assessment of the incidence of documented symptomatic hypoglycaemia with BG ≤3.9 mmol/L over 30 weeks, which was 33.5% in the sitagliptin group and 37.7% in the placebo group, with a between-group difference of −4.1 (95% CI -11.2, 2.9; P = 0.250). According to the prespecified testing strategy (Supporting Information Figure S2) , subsequent hypotheses were not tested for statistical significance, although nominal P values are provided for descriptive purposes.
All key secondary objectives related to hypoglycaemia had incidences (95% CI) that were similar between the sitagliptin and placebo groups ( Table 2 ). An analysis of the distribution of the total number of episodes of hypoglycaemia (1229 in the sitagliptin group and 1441 in the placebo group) is shown in Supporting Information Table S4 .
At week 30, the mean AE SD FPG level was 6.5 AE 1.9 mmol/L in the sitagliptin group and 6.8 Figure 2C ). At week 6, the daily dose of insulin was higher in the placebo group compared with the sitagliptin group, and remained higher throughout the remainder of the treatment period.
| Safety and tolerability
The incidences of adverse events, including those assessed by the investigator as drug-related, were similar between the treatment groups (Table 3) . Two deaths (both cardiovascular-related) were reported, both in the placebo group. There were no clinically meaningful differences in adverse events between treatment groups.
There were no clinically meaningful findings related to laboratory safety measures or vital signs in either treatment group. At week 30, mean AE SD changes from baseline in body weight were 1.5 kg AE 3.4 (sitagliptin) and 1.7 kg AE 3.9 (placebo). In the present study the reduction from baseline FPG at week 30 was also greater in the sitagliptin group than in the placebo group, but in neither treatment group did the mean FPG level reach the study target level of 4.0 to 5.6 mmol/L, and only~30% of participants were at the target level at week 30. Both investigators and participants were instructed to adhere to the insulin titration algorithm, and intensification of insulin therapy was to be limited only by hypoglycaemia events or target achievement. Because the dose of insulin increased throughout the study in both treatment groups, the fact that most participants in both groups did not reach the target FPG range is consistent with uptitration in both groups being limited by a hypoglycaemic event. This result is similar to that observed in another study, in which formulations of insulin glargine were titrated guided by an FPGbased dosing algorithm to a target level of 3.9 to 5.6 mmol/L over 24 weeks 15 ; in that study the mean FPG levels achieved were 6.6 and
| DISCUSSION
It has been demonstrated that the burden of hypoglycaemia, as assessed by event rate and incidence, increases as insulin is titrated to The lack of statistical significance for the hypoglycaemia-related endpoints may be attributable to the fact that the observed event rate was lower than anticipated, rendering the study underpowered for the assessment of hypoglycaemia. Nevertheless, all available evidence from the study supports the concept that continuing sitagliptin does not increase hypoglycaemia compared with discontinuing sitagliptin, despite attainment of greater glycaemic control.
An alternate approach to evaluation of hypoglycaemia would be to consider that if the changes in HbA1c observed over time in the sitagliptin group were replicated in the placebo group (ie, if glycaemic equipoise between the two groups had been achieved in the study, with both groups achieving a mean HbA1c of 51.4 mmol/mol [6.85%]), one would anticipate that greater rates and incidences of hypoglycaemia would have been observed in the placebo group than were observed in the present study. That robust insulin titration was achieved in this study, as evidenced by the titration to an average of 50 to 60 units during the double-blind treatment period, and the fact that there was greater insulin titration in the placebo group, supports the validity of the comparisons of efficacy and of safety as assessed by hypoglycaemia.
As monotherapy, sitagliptin and other DPP-4 inhibitors do not cause hypoglycaemia because of their glucose-dependent mechanism of action; however, when a DPP-4 inhibitor is added to stable doses of insulin, rates of hypoglycaemia can be affected. In a placebocontrolled study in which sitagliptin was added on to ongoing therapy with a stable dose of insulin (with or without metformin), better glycaemic control was accompanied by a higher event rate (1.06 vs. 0.51 events/participant-year) and incidence (16% vs. 8%; P = 0.003) of symptomatic hypoglycaemia with sitagliptin compared to placebo. 16, 17 Alogliptin, 18 linagliptin 19 and saxagliptin 20, 21 added to stable, ongoing insulin treatment did not increase the risk of hypoglycaemia compared with placebo; vildagliptin addition to stable, ongoing insulin treatment has been reported to be associated with both similar 22 and reduced 23 hypoglycaemia rates compared with placebo. In a different treatment paradigm, in participants with inadequate control on insulin (with or without metformin) in which sitagliptin was added on to basal insulin and insulin was intensively titrated, 24 compared with placebo, a lower c % of participants with one or more events during treatment period + 2 weeks (95% CI). d Sitagliptin -placebo (95% CI). e As the P value for the analysis of documented symptomatic hypoglycaemia, BG ≤3.9 mmol/L was >0.05, testing of hypotheses lower in the testing hierarchy could not proceed; therefore this P value is presented only to assist in the comprehensive assessment of hypoglycaemia in the study. event rate (1.7 vs. 3.6 events/participant-year) and incidence of symptomatic hypoglycaemia (25.2% vs. 36.8%; P = 0.001) was observed with sitagliptin compared to placebo. 25 In the present study, which used a clinical treatment paradigm from all previously conducted studies that evaluated the use of DPP-4 inhibitor with insulin in the literature (ie, insulin added on to DPP-4 inhibitor as opposed to DPP-4 inhibitor added on to insulin), the incidence and event rate of hypoglycaemia were similar compared to placebo despite improvements in glycaemic control. Taken together, the results of these studies indicate that it is important to consider how combination therapy with sitagliptin and insulin is initiated when assessing the risk of hypoglycaemia.
Possible mechanisms for the superior glycaemic control without increased hypoglycaemia observed with sitagliptin compared to placebo include the lower dose of insulin used in the sitagliptin group and the DPP-4 inhibitory effect of sitagliptin that stabilizes endogenous GIP. GIP has been demonstrated in preclinical and clinical studies to enhance the glucagon counter-regulatory response during fasting and hypoglycaemic conditions. [7] [8] [9] [10] The stabilization of endogenous GIP with a DPP-4 inhibitor may contribute to attenuation of the tendency for insulin-induced hypoglycaemia.
The effects of combination therapy with a DPP-4 inhibitor and insulin on glycaemic control and hypoglycaemia have some analogies to combination therapy with a GLP-1 agonist and insulin. In studies that compared insulin degludec with a fixed ratio of insulin degludec + liraglutide, significant improvements in glycaemic control were observed. 26, 27 In one of these studies, 26 in which the baseline HbA1c the glargine + sitagliptin group). In the degludec + liraglutide studies, the incidences of hypoglycaemia were either similar between the treatment groups when the insulin doses were equivalent, 26 or lower in the degludec + liraglutide group when the mean insulin dose was lower in that group. 27 Similar findings have been observed with the fixed-ratio combination of glargine + lixisenitide. [28] [29] [30] As with DPP-4 inhibitor + insulin therapy, the GLP-1 agonist component or these fixed-ratio combinations might have beneficial glucose-dependent effects on both α-cell (glucagon-secreting) and β-cell (insulin-secreting) function.
In most studies in which DPP-4 inhibitors were added on to insulin, no significant changes from baseline or between-group differences in doses of insulin were observed; however, in those studies, insulin doses were intended to remain stable. 31 In the above-mentioned study in which sitagliptin was added on to insulin therapy, which was then intensively titrated, 24 that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
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